Log in

Aurinia Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AUPH)

-0.23 (-5.60 %)
(As of 10/15/2019 07:42 AM ET)
Today's Range
Now: $3.88
50-Day Range
MA: $5.57
52-Week Range
Now: $3.88
Volume1.33 million shs
Average Volume1.14 million shs
Market Capitalization$365.85 million
P/E RatioN/A
Dividend YieldN/A
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:AUPH



Sales & Book Value

Annual Sales$460,000.00
Book Value$1.32 per share


Net Income$-64,120,000.00
Net Margins-13,231.97%


Market Cap$365.85 million
Next Earnings Date11/14/2019 (Estimated)

Receive AUPH News and Ratings via Email

Sign-up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter.

Aurinia Pharmaceuticals (NASDAQ:AUPH) Frequently Asked Questions

What is Aurinia Pharmaceuticals' stock symbol?

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) issued its quarterly earnings data on Tuesday, August, 6th. The biotechnology company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.02. The biotechnology company had revenue of $0.03 million for the quarter, compared to analysts' expectations of $0.05 million. Aurinia Pharmaceuticals had a negative return on equity of 50.08% and a negative net margin of 13,231.97%. View Aurinia Pharmaceuticals' Earnings History.

When is Aurinia Pharmaceuticals' next earnings date?

Aurinia Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Aurinia Pharmaceuticals.

What price target have analysts set for AUPH?

7 Wall Street analysts have issued 12 month price targets for Aurinia Pharmaceuticals' stock. Their predictions range from $11.00 to $25.00. On average, they expect Aurinia Pharmaceuticals' share price to reach $16.50 in the next twelve months. This suggests a possible upside of 325.3% from the stock's current price. View Analyst Price Targets for Aurinia Pharmaceuticals.

What is the consensus analysts' recommendation for Aurinia Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aurinia Pharmaceuticals.

What are Wall Street analysts saying about Aurinia Pharmaceuticals stock?

Here are some recent quotes from research analysts about Aurinia Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. " (7/16/2019)
  • 2. HC Wainwright analysts commented, "Buy ILJIN seeks effective control of Aurinia, or at least substantial influence, wholly disproportionate to its current holdings. Over the weekend, Aurinia’s largest shareholder (about 14% S/O), ILJIN SNT Co., Ltd. (private; Seoul, South Korea) launched a proxy contest to elect at least 3 directors to the upcoming Annual General Meeting (AGM) to be held on Wednesday, June 26, 2019. ILJIN is a life science-focused investment fund with a portfolio of positions in about 12 companies (according to its website), including Aurinia which appears to be its largest and longest holding, with a total of about $58M invested since 2010, according to ILJIN." (6/4/2019)

Has Aurinia Pharmaceuticals been receiving favorable news coverage?

News articles about AUPH stock have trended very negative on Tuesday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Aurinia Pharmaceuticals earned a news impact score of -3.8 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Aurinia Pharmaceuticals.

Are investors shorting Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals saw a increase in short interest in September. As of September 30th, there was short interest totalling 7,270,000 shares, an increase of 9.2% from the August 30th total of 6,660,000 shares. Based on an average daily volume of 571,900 shares, the days-to-cover ratio is currently 12.7 days. Approximately 12.1% of the shares of the company are short sold. View Aurinia Pharmaceuticals' Current Options Chain.

Who are some of Aurinia Pharmaceuticals' key competitors?

What other stocks do shareholders of Aurinia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), Array Biopharma (ARRY), Micron Technology (MU), Synergy Pharmaceuticals (SGYP), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL) and Novavax (NVAX).

Who are Aurinia Pharmaceuticals' key executives?

Aurinia Pharmaceuticals' management team includes the folowing people:
  • Mr. Michael R. Martin, Co-Founder & COO
  • Mr. Dennis Bourgeault CPA, C.A., CFO & Sec.
  • Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.
  • Dr. Richard M. Glickman, Advisor (Age 61)
  • Dr. Neil Solomons M.D., Chief Medical Officer

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aurinia Pharmaceuticals' stock price today?

One share of AUPH stock can currently be purchased for approximately $3.88.

How big of a company is Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals has a market capitalization of $365.85 million and generates $460,000.00 in revenue each year. The biotechnology company earns $-64,120,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. Aurinia Pharmaceuticals employs 39 workers across the globe.View Additional Information About Aurinia Pharmaceuticals.

What is Aurinia Pharmaceuticals' official website?

The official website for Aurinia Pharmaceuticals is http://www.auriniapharma.com/.

How can I contact Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals' mailing address is 1203-4464 MARKHAM STREET, VICTORIA A1, V8Z 7X8. The biotechnology company can be reached via phone at 250-744-2487 or via email at [email protected]

MarketBeat Community Rating for Aurinia Pharmaceuticals (NASDAQ AUPH)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  430 (Vote Outperform)
Underperform Votes:  270 (Vote Underperform)
Total Votes:  700
MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote "Outperform" if you believe AUPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel